Artivion, Inc., a leading medical device company specializing in aortic stent grafts, On-X products, and surgical sealants, has released its Form 10-Q report for the third quarter of 2024. The report highlights significant financial growth, strategic initiatives, and the challenges the company faces in the current market environment.
Financial Highlights
Artivion, Inc. reported robust financial performance for the three and nine months ended September 30, 2024: Total Revenues : $95.8 million, a 9% increase compared to the same period in 2023. Total Revenues : $291.2 million for the nine months, a 12% increase compared to the same period in […]
Full Post at www.tradingview.com